TITLE

Specific Medications for Weight Loss

AUTHOR(S)
Jin, Jill
PUB. DATE
August 2015
SOURCE
JAMA: Journal of the American Medical Association;8/18/2015, Vol. 314 Issue 7, p742
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article assesses medications for weight loss. Medications addressed include orlistat, lorcaserin, and the combination of phentermine and topiramate. Also addressed are the combination of bupropion and naltrexone and the medication liraglutide. Other topics include the risks of stimulant drugs for patients with cardiovascular disease, side effects, and the views of the organization Endocrinology Society on the issue.
ACCESSION #
109041450

 

Related Articles

  • Review of the pharmacologic arsenal for the war on obesity. Derbyshire, Mary Beth; Shek, Allen; Szkotak, Jonathan // Formulary;Apr2013, Vol. 48 Issue 4, p136 

    Obesity has become a highly prevalent chronic condition that is associated with significant morbidity and mortality. Studies have demonstrated that even as little as 5% to 10% of weight loss is associated with an improvement in cardiovascular risk factors and a reduction in the incidence of type...

  • The Straight Dope On Weight-Loss Drugs. Fentress, Debbie; Agnew, Bruce // Diabetes Forecast;Apr2002, Vol. 55 Issue 4, p51 

    Provides information on weight-loss drugs, Xenical, Meridia and phentermine. Overview of studies on the drugs; Side effects of weight loss drugs; Contents of the drugs. INSET: Beware herbal remedies.

  • THE NEW PRESCRIPTIONS.  // Marie Claire (US Edition);Oct2012, Vol. 19 Issue 10, p270 

    The article offers a preview on the two diet medications approved by the U.S. Food and Drug Administration (FDA), the Belviq and the combined phentermine and topiramate drug called Qsymia and another drug, the Contrave, which is to be reviewed by the agency after it was rejected in 2011.

  • Topiramate withdrawal.  // Reactions Weekly;6/2/2007, Issue 1154, p22 

    The article presents a case report of an obese man who experienced rebound weight gain following topiramate withdrawal. The man had a body mass index of 32 and a history of multiple dietary treatments followed by weight gain and an unsuccessful orlistat treatment. The man stopped further...

  • The skinny on errors with obesity drug names.  // Pharmacy Today;May2015, Vol. 21 Issue 5, p88 

    The article offers information on medications related to or used in the treatment of obesity. Topics discussed include potential confusion between the trade names Xeloda, an anticancer medication, and Xenical, an antiobesity drug, rules created by a hospital unto its computer system to alert...

  • ARE DIET-DRUG COMBOS SAFE? Goad, Kimberly // Health (Time Inc.);Jun2011, Vol. 25 Issue 5, p143 

    The article focuses on the consumption safety of weight-loss drug mixes. The phentermine-topiramate mix can result to 9 percent more weight lost than consuming a placebo, although it can lead to birth defects and heart diseases. The bupropion-naltrexone combination can result to 4.2 percent more...

  • Orlistat: A Viewpoint by F. Xavier Pi-Sunyer. Pi-Sunyer, F.X. // Drugs;Aug1998, Vol. 56 Issue 2, p250 

    Offers views on the anti-obesity drug orlistat. Mechanism of actio; Toxicity; Effectiveness.

  • Orlistat: A Viewpoint by Madeleine L. Drent. Drent, M.L. // Drugs;Aug1998, Vol. 56 Issue 2, p250 

    Offers views on the anti-obesity drug orlistat. Physiological effects of orlistat; Effectiveness; Adverse effects.

  • Orlistat. McNeely, W.; Benfield, P. // Drugs;Aug1998, Vol. 56 Issue 2, p241 

    â–´ Orlistat (tetrahydrolipstatin) is an inhibitor of pancreatic and other lipases. As a pancreatic lipase inhibitor, it acts in the gastrointestinal lumen and is indicated for use in obesity. â–´ Serum total cholesterol and low density lipoprotein-cholesterol levels were reduced in...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics